304 related articles for article (PubMed ID: 6117290)
1. Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system.
Kaneko T; Kitahara A; Ozaki S; Takizawa K; Yamatsu K
Arzneimittelforschung; 1981; 31(8):1206-12. PubMed ID: 6117290
[TBL] [Abstract][Full Text] [Related]
2. Effects of azelastine hydrochloride, a new antiallergic drug, on the gastrointestinal tract.
Yamanaka T; Shoji T; Murakami M; Igarashi T
Arzneimittelforschung; 1981; 31(8):1203-6. PubMed ID: 6117289
[TBL] [Abstract][Full Text] [Related]
3. Anti-allergic properties of a new histamine antagonist, 4-(p-chlorobenzyl)-2- [N-methyl-perhydroazepinyl-(4)]-1-(2H)-phthalazinone hydrochloride (azelastine).
Tasaka K; Akagi M
Arzneimittelforschung; 1979; 29(3):488-93. PubMed ID: 90510
[TBL] [Abstract][Full Text] [Related]
4. Effect of azelastine hydrochloride on vascular permeability in hypersensitivity reaction skin site in guinea pig.
Tanigawa T; Honda M; Miura K
Arzneimittelforschung; 1981; 31(8):1212-5. PubMed ID: 6117291
[TBL] [Abstract][Full Text] [Related]
5. Central effect of the potent long-acting H1-antihistamine levocabastine.
Tasaka K; Kamei C; Tsujimoto S; Yoshida T; Aoki I
Arzneimittelforschung; 1990 Dec; 40(12):1295-9. PubMed ID: 1982750
[TBL] [Abstract][Full Text] [Related]
6. General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate. 1st communication: effects on the central nervous system.
Saito T; Fukuda T; Sukamoto T; Yoshidomi M; Morimoto Y; Shimohara K; Ito K
Arzneimittelforschung; 1988 Jan; 38(1):66-9. PubMed ID: 2896509
[TBL] [Abstract][Full Text] [Related]
7. Inhibition by azelastine of the immunologically induced histamine release from isolated guinea pig mast cells.
Fischer B; Schmutzler W
Arzneimittelforschung; 1981; 31(8):1193-5. PubMed ID: 6170297
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (5) Action of M73101 on the central nervous system (author's transl)].
Sato M
Nihon Yakurigaku Zasshi; 1979 Oct; 75(7):695-706. PubMed ID: 575516
[TBL] [Abstract][Full Text] [Related]
9. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on central nervous and sensory systems and other functions.
Yamamoto S; Takemori E; Hasegawa Y; Nakao K; Inukai T; Nomura M; Morino K; Tsuchiyama M; Hasegawa K; Ikeda H
Arzneimittelforschung; 1991 Jun; 41(6):602-7. PubMed ID: 1930347
[TBL] [Abstract][Full Text] [Related]
10. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T
Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
[TBL] [Abstract][Full Text] [Related]
11. [Effects of suloctidil on the central and peripheral nervous systems].
Nishi H; Watanabe T; Mori M
Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248
[TBL] [Abstract][Full Text] [Related]
12. Effects of antihistaminic drugs in tests for antidepressant action.
Rogóz Z; Skuza G; Sowińska H
Pol J Pharmacol Pharm; 1981 Oct; 33(3):321-35. PubMed ID: 6119682
[TBL] [Abstract][Full Text] [Related]
13. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
Shintani S; Toba Y; Suzuki S; Ninomiya S; Umezato M; Hiyama T
Arzneimittelforschung; 1985; 35(7A):1157-62. PubMed ID: 4074429
[TBL] [Abstract][Full Text] [Related]
14. [Effects of ritodrine hydrochloride on motor nervous system and central nervous system].
Ikeda S; Tsukamoto T
Nihon Yakurigaku Zasshi; 1984 Sep; 84(3):311-26. PubMed ID: 6500405
[TBL] [Abstract][Full Text] [Related]
15. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
Murata T; Sakaya S; Hoshino T; Umetsu T; Hirano T; Nishio S
Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems.
Hirohashi M; Takasuna K; Kasai Y; Usui C; Kojima H
Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of amezinium, a novel antihypotensive drug. VI. Effect on central nervous functions.
Teschendorf HJ; Kretzschmar R; Kreiskott H; Weifenbach H
Arzneimittelforschung; 1981; 31(9a):1580-8. PubMed ID: 7197973
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological study of mequitazine (LM-209) (III). Action on the central nervous system (author's transl)].
Fujimura H; Tsurumi K; Yanagihara M; Hiramatsu Y; Tamura Y; Shimizu Y; Hojo M; Yoshida Y; Serizawa I
Nihon Yakurigaku Zasshi; 1981 Oct; 78(4):249-60. PubMed ID: 6120125
[TBL] [Abstract][Full Text] [Related]
19. [Effect of the antihistamine preparation, phencarol, on the central nervous system].
Kaminka ME; Roshchina LF; Mashkovskiĭ MD
Farmakol Toksikol; 1980; 43(2):148-53. PubMed ID: 6108233
[TBL] [Abstract][Full Text] [Related]
20. Animal experiments on the safety pharmacology of lofexidine.
Graf E; Sieck A; Wenzl H; Winkelmann J
Arzneimittelforschung; 1982; 32(8a):931-40. PubMed ID: 6890367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
